> FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
An AOD 9604 peptide review should begin with lot identity, not promotional language. For laboratory buyers, the relevant questions are straightforward: Does the material match the stated sequence? Is purity supported by batch-specific analytical data? Can the supplier document manufacturing and handling controls? AOD 9604 is a research compound only and is not intended for human consumption.
Author: Research Team at The Peptide Source
AOD 9604 at a Glance
AOD 9604 is a synthetic peptide corresponding to residues 176-191 of human growth hormone. Its commonly reported sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, written in one-letter notation as YLRIVQCRSVEGSCGF.
The expected molecular weight of the free peptide is approximately 1,815.1 Da. Actual vial mass can vary when the material is supplied as a salt, such as acetate, or when residual water content is reported separately. A credible certificate of analysis should identify the lot, material form, analytical method, reported purity, and testing date rather than relying on a generic specification sheet.
> Compliance Notice
>
> FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. AOD 9604 is supplied solely for qualified laboratory research and analytical investigation. It is not a food, drug, dietary supplement, diagnostic product, or consumer-use material. It must not be used in humans or animals.
What a Useful AOD 9604 Peptide Review Should Examine
The peptide market makes it easy to compare vial labels and difficult to compare underlying evidence. A meaningful review separates catalog claims from batch-level documentation. A stated purity figure, even one above 99%, is useful only when it is connected to a defined analytical method and a specific production lot.
For AOD 9604, reverse-phase HPLC is typically used to estimate chromatographic purity. The chromatogram should show the principal peak, retention time, integration method, and any reportable secondary peaks. HPLC purity alone does not establish sequence identity. Mass spectrometry is the complementary check because it confirms whether the observed molecular mass aligns with the expected peptide mass and stated salt form.
The strongest supplier documentation combines HPLC and mass spectrometry, then ties both results to a lot number that appears on the vial or outer label. Manufacturer documentation is valuable, but independent third-party verification provides an additional control against transcription errors, substituted material, and unsupported purity claims.
For a research workflow, traceability matters as much as the headline percentage. The chain should be clear from production lot to COA, fulfillment record, and retained sample policy where applicable. If a supplier cannot provide batch-specific documentation, the prudent assumption is that the material has not been adequately verified for controlled research use.
AOD 9604 Sequence and Analytical Identity
Sequence confirmation
The stated 16-residue sequence contains two cysteine residues. That detail matters during analytical review because cysteine-containing peptides can present handling and storage considerations, including oxidation-related secondary species. A chromatogram with a single dominant peak is encouraging, but it should be interpreted alongside mass data and the laboratory's stated method conditions.
Sequence identity may be evaluated by intact-mass analysis, peptide mapping, or both. Intact-mass analysis is efficient for routine lot confirmation. Peptide mapping can offer greater structural resolution, particularly when a laboratory is evaluating potential truncations, deletions, or oxidation products. The appropriate method depends on the purpose of the study and the level of characterization required by the protocol.
Purity is not the same as identity
A purity result of >99% by HPLC describes the relative area of a principal chromatographic peak under specified conditions. It does not, by itself, prove that the peak is the intended sequence. Likewise, a matching mass result does not fully describe chromatographic impurities. Research buyers should view HPLC and mass spectrometry as paired controls, not interchangeable claims.
The Peptide Source positions its research-grade inventory around a stated 99% purity standard, manufacturer COAs, and additional third-party verification. For any purchase decision, the current lot's documents should remain the controlling record. A general site statement is not a substitute for the COA associated with the vial received.
Research Context and Mechanistic Limits
AOD 9604 is commonly described in scientific literature as a C-terminal growth hormone fragment. Researchers have investigated this sequence in cell-based and preclinical models involving lipid handling, signaling pathways, and peptide structure-function relationships. These are research observations, not evidence for any human, veterinary, therapeutic, or performance use.
Mechanistic descriptions require restraint. The full-length growth hormone molecule has a defined receptor biology, but a short synthetic fragment should not be assumed to reproduce that biology. Published discussions have proposed interactions involving lipid-metabolism signaling in laboratory models, while the direct molecular target and the relevance of individual findings remain subject to experimental conditions. Cell type, assay duration, peptide concentration, formulation, and species can all affect observed results.
For that reason, a supplier review should not treat mechanistic language as a proxy for material quality. The operational question is narrower: whether the supplied peptide is analytically consistent with the sequence specified for the experiment. Research teams should evaluate published primary literature independently, record database search dates, and cite original PubMed-indexed studies and DOIs in their own protocols rather than relying on vendor summaries.
COA Standards for AOD 9604 Research Material
A batch-specific COA should be readable without interpretation by a sales representative. At minimum, it should identify the compound, lot number, date, analytical laboratory or testing party, purity result, and method used. For AOD 9604, an expected mass or mass-spectrum result should also be included.
A stronger packet may include raw or representative HPLC chromatograms, mass-spectrum output, residual solvent testing where relevant, moisture data, microbial testing when applicable to the research format, and storage instructions. Not every analysis is necessary for every project, but the supplier should be precise about what was tested and what was not tested.
Be cautious with COAs that lack a lot number, show only a typed purity percentage, use an unverifiable laboratory name, or display identical results across multiple batches. Those patterns do not automatically establish a problem, but they justify a request for clarification before the material enters a study.
Storage and handling documentation
Storage requirements should follow the supplier's lot-specific instructions. In general, researchers should minimize unnecessary exposure to heat, moisture, and repeated temperature cycling, maintain container integrity, and document internal aliquoting or solution preparation under their own laboratory procedures. The appropriate solvent system, concentration range, and stability window are method-dependent and should be established by the investigating laboratory.
A supplier should not present generalized handling statements as validated stability data. If stability after reconstitution is central to the protocol, researchers should verify it using an appropriate analytical method under their actual storage and use conditions.
Buying Criteria for Laboratory Teams
For experienced purchasers, AOD 9604 sourcing comes down to documentation, identity, and logistics. Same-day US fulfillment can reduce procurement delays, but speed should never outrank verification. Confirm the current COA before ordering when the material will be used in a time-sensitive or controlled study.
Ask whether the material is produced in a controlled facility, whether the COA is lot-specific, whether third-party results are available, and how the lot is labeled through fulfillment. These are practical controls that support reproducibility. Price is relevant, but a lower price without traceable analytical evidence can create a larger cost later through failed method development, inconsistent results, or unusable material.
> FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. AOD 9604 must be handled only within lawful laboratory research settings by qualified personnel. No material discussed here is intended for human or animal administration.
The most useful next step is simple: review the current lot documentation before committing the peptide to a protocol. A clear sequence, a matching mass result, defensible HPLC data, and traceable fulfillment records provide a better foundation for research than any unverified product claim.